From Casetext: Smarter Legal Research

In re Lorazepam Clorazepate Antitrust Litigation

United States District Court, D. Columbia
Sep 19, 2002
MDL-1290 (TFH/JMF), Misc. No. 99ms276, CV 1:99-790 (TFH/JMF), CV 1:99-2228 (N.D. Ill.) (D.D.C. Sep. 19, 2002)

Opinion

MDL-1290 (TFH/JMF), Misc. No. 99ms276, CV 1:99-790 (TFH/JMF), CV 1:99-2228 (N.D. Ill.)

September 19, 2002


ORDER


This matter is before the Court on the motion of defendants Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc. and UDL Laboratories, Inc. for leave to file a short supplemental memorandum not to exceed two pages in opposition to Class Plaintiffs' Motion to Reset Briefing Schedule. Upon consideration of the motion and the record herein, it is hereby ORDERED that the motion be, and it hereby is, GRANTED.


Summaries of

In re Lorazepam Clorazepate Antitrust Litigation

United States District Court, D. Columbia
Sep 19, 2002
MDL-1290 (TFH/JMF), Misc. No. 99ms276, CV 1:99-790 (TFH/JMF), CV 1:99-2228 (N.D. Ill.) (D.D.C. Sep. 19, 2002)
Case details for

In re Lorazepam Clorazepate Antitrust Litigation

Case Details

Full title:IN RE: LORAZEPAM CLORAZEPATE ANTITRUST LITIGATION This document relates…

Court:United States District Court, D. Columbia

Date published: Sep 19, 2002

Citations

MDL-1290 (TFH/JMF), Misc. No. 99ms276, CV 1:99-790 (TFH/JMF), CV 1:99-2228 (N.D. Ill.) (D.D.C. Sep. 19, 2002)